Lipitas 40mg Tablet contains Rosuvastatin, a potent lipid-lowering agent belonging to the statin class, indicated for the management of hypercholesterolemia and mixed dyslipidemia. Rosuvastatin acts by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Lipitas 40mg is prescribed to patients at high risk of cardiovascular events, including those with established coronary artery disease, diabetes mellitus, or multiple risk factors for atherosclerosis. The recommended dosage should be individualized based on patient response and lipid profile, with regular monitoring of liver function tests and creatine kinase levels to detect potential adverse effects such as hepatotoxicity or myopathy. Contraindications include active liver disease, pregnancy, and hypersensitivity to rosuvastatin or its components. Caution is advised when co-administered with other lipid-lowering agents or drugs metabolized via the cytochrome P450 system to avoid drug interactions. Lifestyle modifications, including diet and exercise, should accompany pharmacotherapy to optimize therapeutic outcomes. Lipitas 40mg provides an effective option for achieving target lipid levels and reducing cardiovascular morbidity and mortality in appropriate patient populations.